Bayer’s results beat, debt eases and legal strategy gains traction

Bayer’s latest update arrived with several moving parts at once: better-than-expected quarterly earnings, a lower debt outlook and fresh confirmation that the company sees its legal position in the glyphosate fight improving. For investors, the combination was enough to push the shares higher, even as some parts of the business remain under pressure.

The Leverkusen group said on Tuesday that adjusted EBITDA came in at EUR 2.144 billion in the second quarter of 2026, up 1.9 percent from the same period a year earlier. Core EPS was EUR 0.95. Chief executive Bill Anderson also reaffirmed the company’s currency-adjusted full-year outlook and, according to Bayer IR and Reuters, pointed to “decisive progress” in the legal strategy around glyphosate.

The market response was immediate. Bayer stock rose 3.84 percent during the day to EUR 49.20. That leaves the shares up 32.94 percent since the start of the year. The recovery has been building since the 52-week low in August 2025.

One of the main reasons for the improved mood was the debt outlook. Bayer cut its forecast for net financial debt at the end of 2026 to a range of EUR 29 billion to EUR 30 billion, below previous expectations. Media reports said the lower target is mainly linked to an agreed sale of a stake in the contraception business to Apollo Global Management. The move helps the balance sheet without requiring the company to give up strategically central assets.

Cash generation, however, was weaker. Free cash flow in the second quarter was minus EUR 371 million, compared with plus EUR 125 million in the prior-year quarter. According to Bayer IR and reports from Aktionär, that deterioration was largely driven by settlement payments tied to US litigation. It is a reminder that the legal overhang is still influencing the numbers, even after the stronger operating performance.

Should investors sell immediately? Or is it worth buying Bayer?

The business mix inside Bayer remains uneven. Crop Science lifted sales of glyphosate-based herbicides by 12.6 percent in the second quarter, with the EMEA region making the biggest contribution. Pharma, by contrast, continued to feel the effect of the Xarelto patent expiry, with sales down 42 percent, while Eylea also faced rising competitive pressure. Growth from Nubeqa, up 57 percent, and Kerendia, up 84 percent, is helping to offset those declines, with both drugs posting clear volume gains.

On the legal front, Anderson’s comments were backed by a concrete development at the end of June, when the US Supreme Court ruled 7 to 2 in the Durnell case that federal law pre-empts individual state claims over allegedly missing warning labels if the EPA has confirmed the product’s safety. Bayer said it views that ruling as an important boost to its position in the planned class settlement in the glyphosate cases.

The company is also pushing for broader political change in the US. Through the Modern Ag Alliance, now bringing together more than 360 associations, Bayer is advocating federal labelling legislation for agricultural products. The aim is to increase long-term legal certainty for glyphosate-based products and reduce the number of new lawsuits.

Not every part of the market reaction was enthusiastic. Jefferies & Company initially rated Bayer shares “Hold” after the half-year report. Still, Tuesday’s price action suggests that some investors are giving more weight to the mix of solid operating earnings, a lighter debt forecast and better legal positioning than to the cautious broker note.